Search Results - "Botta, Gregory"

SMARCA4 : Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy by Mardinian, Kristina, Adashek, Jacob J, Botta, Gregory P, Kato, Shumei, Kurzrock, Razelle

“…The SWI/SNF chromatin remodeling complex, via nucleosome topology modulation, regulates transcription. The SMARCA4 (BRG1) subunit codes for the ATPase energy…”
Get full text

Electrospun hydroxyapatite-containing chitosan nanofibers crosslinked with genipin for bone tissue engineering by Frohbergh, Michael E, Katsman, Anna, Botta, Gregory P, Lazarovici, Phillip, Schauer, Caroline L, Wegst, Ulrike G.K, Lelkes, Peter I

“…Abstract Reconstruction of large bone defects remains problematic in orthopedic and craniofacial clinical practice. Autografts are limited in supply and are…”
Get full text

Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases by Baumgartner, Joel M., Botta, Gregory P.

“…Purpose This was a review of circulating tumor DNA (ctDNA) in patients with peritoneal metastases from colorectal cancer. Methods We searched the PubMed…”
Get full text

Tumor-penetrating therapy for β5 integrin-rich pancreas cancer by Hurtado de Mendoza, Tatiana, Mose, Evangeline S., Botta, Gregory P., Braun, Gary B., Kotamraju, Venkata R., French, Randall P., Suzuki, Kodai, Miyamura, Norio, Teesalu, Tambet, Ruoslahti, Erkki, Lowy, Andrew M., Sugahara, Kazuki N.

“…Pancreatic ductal adenocarcinoma (PDAC) is characterized by marked desmoplasia and drug resistance due, in part, to poor drug delivery to extravascular tumor…”
Get full text

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer by Botta, Gregory P, Kato, Shumei, Patel, Hitendra, Fanta, Paul, Lee, Suzanna, Okamura, Ryosuke, Kurzrock, Razelle

“…BACKGROUNDImmune checkpoint inhibitors (ICIs) fail to demonstrate efficacy in pancreatic cancer. Recently, genomic biomarkers have been associated with…”
Get full text

Isolation, culture and genetic manipulation of mouse pancreatic ductal cells by Reichert, Maximilian, Takano, Shigetsugu, Heeg, Steffen, Bakir, Basil, Botta, Gregory P, Rustgi, Anil K

“…The most common subtype of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC). PDAC resembles duct cells morphologically and, to some extent, at a…”
Get full text

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma by Azzi, Georges, Tavallai, Mehrad, Aushev, Vasily N, Koyen Malashevich, Allyson, Botta, Gregory P, Tejani, Mohamedtaki A, Hanna, Diana, Krinshpun, Shifra, Malhotra, Meenakshi, Jurdi, Adham, Aleshin, Alexey, Kasi, Pashtoon M

“…Abstract Background Anal squamous cell carcinoma (SCCA) is an uncommon malignancy with a rising incidence that has a high cure rate in its early stages. There…”
Get full text

Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma by Botta, Gregory P, Abdelrahim, Maen, Drengler, Ronald L, Aushev, Vasily N, Esmail, Abdullah, Laliotis, George, Brewer, Chris M, George, Giby V, Abbate, Steven M, Chandana, Sreenivasa R, Tejani, Mohamedtaki A, Malla, Midhun, Bansal, Dhruv, Rivero-Hinojosa, Samuel, Spickard, Erik, McCormick, Nicole, Cecchini, Michael, Lacy, Jill, Fei, Naomi, Kasi, Pashtoon Murtaza, Kasi, Anup, Dayyani, Farshid, Hanna, Diana L, Sharma, Shruti, Malhotra, Meenakshi, Aleshin, Alexey, Liu, Minetta C, Jurdi, Adham

“…Personalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible and allows for molecular residual disease (MRD) identification in patients…”
Get full text

Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC) by Elzein, Safa, Bao, Fei, Lin, Ray, Schnickel, Gabriel, Lowy, Andrew M., Botta, Gregory P.

“…Abstract Background Primary small cell carcinoma of the pancreas (SCCP) is a rare malignant neuroendocrine carcinoma (NEC). Typically, it presents with…”
Get full text

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis by Shaya, Justin, Kato, Shumei, Adashek, Jacob J., Patel, Hitendra, Fanta, Paul T., Botta, Gregory P., Sicklick, Jason K., Kurzrock, Razelle

“…Despite progress, 2-year pancreatic cancer survival remains dismal. We evaluated a biomarker-driven, combination/N-of-one strategy in 18 patients…”
Get full text

Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients by Botta, Gregory P., Huynh, Tridu R., Spierling‐Bagsic, Samantha R., Agelidis, Alexander, Schaffer, Randolph, Lin, Ray, Sigal, Darren

“…Background There is no agreed upon standard of care for borderline‐resectable pancreatic cancer (BRPC) or locally‐advanced pancreatic cancer (LAPC) patients…”
Get full text

Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers by Huffman, Brandon M, Aushev, Vasily N, Budde, Griffin L, Chao, Joseph, Dayyani, Farshid, Hanna, Diana, Botta, Gregory P, Catenacci, Daniel V T, Maron, Steven B, Krinshpun, Shifra, Sharma, Shruti, George, Giby V, Malhotra, Meenakshi, Jurdi, Adham, Moshkevich, Solomon, Aleshin, Alexey, Kasi, Pashtoon M, Klempner, Samuel J

“…Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA…”
Get more information

Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells by Botta, Gregory P, Chao, Joseph, Ma, Hong, Hahn, Michael, Sierra, Gloria, Jia, Jie, Hendrix, Amanda Y, Nolte Fong, Joy V, Ween, Audrey, Vu, Peter, Miller, Aaron, Choi, Michael, Heyman, Benjamin, Daniels, Gregory A, Kaufman, Dan, Jamieson, Catriona, Li, Zonghai, Cohen, Ezra

“…Treatment of hematologic malignancies with patient-derived anti-CD19 chimeric antigen receptor (CAR) T-cells has demonstrated long-term remissions for patients…”
Get full text

Hemorrhagic Cystitis: Treatment With Hyperbaric Oxygen Therapy in Patients With Acute Lymphoblastic Leukemia by Botta, Lauren M, Botta, Gregory P

“…Hyperbaric oxygen therapy is a rare treatment modality for hemorrhagic cystitis (HC) following BK virus reactivation in the immunosuppressed population…”
Get full text

Challenges and prospects of CSF1R targeting for advanced malignancies by Moeller, Ann, Kurzrock, Razelle, Botta, Gregory P, Adashek, Jacob J, Patel, Hitendra, Lee, Suzanna, Pabla, Sarabjot, Nesline, Mary K, Conroy, Jeffrey, Sicklick, Jason K, Kato, Shumei

“…CSF1R expression modulates tumor-associated macrophages, making CSF1R blockade an appealing immune-modulating therapeutic target. We evaluated the correlation…”
Get full text

Advances on immunotherapy in genitourinary and renal cell carcinoma by Botta, Gregory P., Granowicz, Eric, Costantini, Carrie

“…Genitourinary (GU) cancers are a group of epithelial malignancies associated with the organs involved in the excretion of urine. Renal cell, urothelial, and…”
Get full text

Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1 by Botta, Gregory P, Reginato, Mauricio J, Reichert, Maximilian, Rustgi, Anil K, Lelkes, Peter I

“…Pancreatic ductal adenocarcinomas (PDAC) are highly invasive and metastatic neoplasms commonly unresponsive to current drug therapy. Overwhelmingly, PDAC…”
Get full text

ERK2-regulated TIMP1 induces hyperproliferation of K-Ras(G12D)-transformed pancreatic ductal cells by Botta, Gregory P, Reichert, Maximilian, Reginato, Mauricio J, Heeg, Steffen, Rustgi, Anil K, Lelkes, Peter I

“…Pancreatic ductal adenocarcinoma (PDAC) commonly contains a mutation in K-Ras(G12D) and is characterized by a desmoplastic reaction composed of deregulated,…”
Get full text

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy by Louie, Bryan H., Kato, Shumei, Kim, Ki Hwan, Lim, Hyo Jeong, Okamura, Ryosuke, Eskander, Ramez N., Botta, Gregory, Patel, Hitendra, Lee, Suzanna, Lippman, Scott M., Sicklick, Jason K., Kurzrock, Razelle

“…Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of…”
Get full text

Reversible intrahepatic cholestasis in metastatic prostate cancer: An uncommon paraneoplastic syndrome by Li, Zuwei, Zhou, Liang, Zhao, Liwen, Chen, Peijie, Liu, Yifeng, Ding, Yu, Sun, Shuolei, Yang, Shangqi, Lai, Yongqing

“…As with other genitourinary malignancies, a variety of paraneoplastic syndromes have been revealed to occur in patients with prostate cancer. Stauffer's…”
Get full text